clinical trial · NCT06971900
GATEWAY: A Phase 2a Study of PORT-77 in Adults With Erythropoietic Protoporphyria
Portal Therapeutics, Inc.·phase2·enrolling by invitation·n = 14
Erythropoietic Protoporphyria (EPP)PORT-77Placebo
brief summary
A Phase 2a study of PORT-77 in adults with erythropoietic protoporphyria (EPP)
started
Apr 4, 2025
primary completion
Jan 1, 2026
completion
Jan 1, 2026
last updated
May 14, 2025
official title
A Phase 2a, Blinded, Randomized, Placebo-Controlled Study of PORT-77 Administered Orally to Adults With Erythropoietic Protoporphyria
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol